UnknownPHASE2, PHASE3NCT00348153

Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)

Studying Uveitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Heidelberg University
Principal Investigator
Hannes M Lorenz, MD
Department of Rheumatology, University of Heidelberg
Intervention
Adalimumab(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20062013

Study locations (1)

Collaborators

Abbott

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00348153 on ClinicalTrials.gov

Other trials for Uveitis

Additional recruiting or active studies for the same condition.

See all trials for Uveitis

← Back to all trials